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OBJECTIVE — Associations between metabolic syndrome and its individual components
with risk of incident dementia and its different subtypes are inconsistent.
RESEARCH DESIGN AND METHODS — The 7,087 community-dwelling subjects
aged 65 years were recruited from the French Three-City (3C) cohort. Hazard ratios (over 4
years) of incident dementia and its subtypes (vascular dementia and Alzheimer’s disease) and
association with metabolic syndrome (deﬁned according to the National Cholesterol Education
Program Adult Treatment Panel III criteria) and its individual components (hypertension, large
waist circumference, high triglycerides, low HDL cholesterol, and elevated fasting glycemia)
were estimated in separate Cox proportional hazard models.
RESULTS — Metabolic syndrome was present in 15.8% of the study participants. The pres-
enceofmetabolicsyndromeincreasedtheriskofincidentvasculardementiabutnotAlzheimer’s
disease over 4 years, independent of sociodemographic characteristics and the apolipoprotein
(apo)Eε 4allele.Hightriglyceridelevelwastheonlycomponentofmetabolicsyndromethatwas
signiﬁcantly associated with the incidence of all-cause (hazard ratio 1.45 [95% CI 1.05–2.00];
P  0.02) and vascular (2.27 [1.16–4.42]; P  0.02) dementia, even after adjustment of the
apoE genotype. Diabetes, but not impaired fasting glycemia, was signiﬁcantly associated with
all-cause (1.58 [1.05–2.38]; P  0.03) and vascular (2.53 [1.15–5.66]; P  0.03) dementia.
CONCLUSIONS — Theobservedrelationbetweenhightriglycerides,diabetes,andvascular
dementia emphasizes the need for detection and treatment of vascular risk factors in older
individuals in order to prevent the likelihood of clinical dementia.
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D
ementia is the most severe form of
pathological brain aging, deﬁned
by the coexistence of memory dis-
orders and deﬁcit in at least one other
cognitive function (impairment of ab-
stractthinking;impairedjudgment;other
disturbances of higher cortical function,
such as aphasia, apraxia, agnosia, or con-
structional difﬁculty; or personality
change), with a signiﬁcant impact on ac-
tivities of daily living (1). Eighteen per-
cent of people aged 75 years have
dementia. Its most frequent form is Alz-
heimer’s disease (50–60% of cases)
([1]), vascular dementia accounting for
most of the other causes (1). The under-
lying pathophysiological mechanisms,
and hence risk factors, of Alzheimer’s dis-
easeandvasculardementiaremainuncer-
tain (2), and no etiologic treatment is
available yet. Nevertheless, several poten-
tially modiﬁable risk factors of dementia
havebeenidentiﬁed.Hypertension,espe-
cially in mid-life, increases the likelihood
ofdevelopingdementia(3).Althoughless
studied, obesity (4) and dyslipidemia (5)
are also being recognized as possible
modiﬁable risk factors of dementia. Some
studies have shown that diabetes in-
creases the risk of developing dementia
(6). These factors usually coexist under
the heading of metabolic syndrome,
which is a cluster of ﬁve cardiovascular
risk factors including hypertension, ab-
dominal obesity, high triglycerides, low
HDL cholesterol, and elevated fasting
glycemia (impaired fasting glucose or
diabetes) (7).
Metabolic syndrome is associated
with increased risk of cardiovascular dis-
ease (8). If metabolic syndrome were also
associated with increased risk of develop-
ing dementia, the screening and manage-
ment of its components might offer
avenues for prevention of cardiovascular
disease and dementia as well. However,
the association between metabolic syn-
drome, or its individual components, and
dementia has received little attention (9–
14). Three longitudinal studies (10–12)
showed that metabolic syndrome as a
wholeisrelatedtohigherriskofcognitive
decline, but they did not examine the as-
sociationwiththeriskofdementia.While
a cross-sectional study (13) found a
higher prevalence of dementia in women
withmetabolicsyndrome,thesinglepub-
lished prospective study (14) showed no
association between metabolic syndrome
and incident dementia. On the other
hand, only some components of the met-
abolic syndrome (and not the metabolic
syndrome itself) might be associated with
an increased risk of incident dementia. In
particular, several prospective studies ev-
idenced that the presence of diabetes was
associated with increased incidence of
Alzheimer’s disease and vascular demen-
tia (6,14). However, the role of hypergly-
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(impaired fasting glucose) needs to be
well deﬁned (15).
We therefore aimed to estimate the
prospective association between meta-
bolic syndrome, or its individual compo-
nents, with the risk of incident dementia
and the potential differences according to
the subtype of dementia: Alzheimer’s dis-
ease or vascular dementia, in a large pro-
spective epidemiological study
conducted in community-dwelling older
subjects. We focused on the component
“elevated fasting glycemia” to study the
speciﬁc role of diabetes versus impaired
fasting glucose.
RESEARCH DESIGN AND
METHODS— The subjects included
in the present study were a subsample of
the Three-City (3C) Study, a large French
multicenter prospective epidemiologic
study of vascular risk factors for demen-
tia. The study protocol has been de-
scribedpreviously(16)andwasapproved
by the Consultative Committee for the
ProtectionofPersonsParticipatinginBio-
medical Research of the University Hos-
pital of Kremlin-Bice ˆtre (Paris, France).
All participants gave their written in-
formedconsent.Brieﬂy,noninstitutional-
ized subjects aged 65 years were
selected from electoral rolls of three cities
andtheirsuburbs(Bordeauxinthesouth-
west, Dijon in the northeast, and Mont-
pellier in the southeast of France) and
then invited to participate in the study.
Sample size was estimated to achieve a
sufﬁcient number of health events over 4
years. At baseline in 1999–2000, the
sample included 9,294 subjects (3,718
men and 5,576 women; 2,104 in Bor-
deaux, 4,931 in Dijon, and 2,259 in
Montpellier).
For the present study of incident de-
mentia (screening procedure described
below), we excluded 215 participants al-
ready demented at baseline (1999–
2000). We also excluded 1,341 subjects
because of incomplete data for deﬁning
metabolic syndrome (623 subjects with
no blood samples and 971 with no waist
circumference measurement). This gave a
baseline sample of 7,738 subjects. At the
second round of the study (2001–2002),
6,964 (90.0%) subjects were examined
again, 134 were deceased, and 640 re-
fused to participate or were lost to follow-
up. At the third round (2003–2004),
6,262 subjects were examined (84.9% of
the survivors after the second round), the
cumulated number of deaths was 358,
and 1,118 refused to participate or were
lost to follow-up. Finally, 7,087 (91.6%)
participantshadatleastonefollow-upex-
amination over 4 years and formed the
sample of the present study.
Diagnosis of dementia
A three-step procedure was used to diag-
nosecasesofdementia(16).First,screen-
ing was based on a thorough
neuropsychological examination by
trained psychologists. This examination
included a battery of cognitive tests cov-
ering memory, attention, language, and
visuo-spatialabilities.Dataonactivitiesof
daily living, severity of cognitive disor-
ders, and, where possible, magnetic reso-
nance images or computed tomography
scans were collected (16). Second, the
participants who were suspected of hav-
ing dementia on the basis of their neuro-
psychological performance (in particular
the Mini Mental Status Examination, the
Benton Visual Retention Test, and the
Isaac’s Set Test administered uniformly in
all three study centers at each follow-up
[16]) were examined by a neurologist in
the three study centers (16). Finally, all
suspected dementia cases were analyzed
by a common independent committee of
neurologists according to the criteria of
the DSM-IV (16). This committee of neu-
rologists reviewed by teleconference all
potential cases of dementia of the three
study centers to obtain a consensus on its
diagnosis and etiology based on all exist-
ing information. With regard to the dif-
ferent subtypes of dementia, we
considered the two most frequent causes
of dementia as determined by committee
(Alzheimer’s disease according to Na-
tional Institute of Neurological and Com-
municative Disorders and Stroke and the
Alzheimer’s Disease and Related Disor-
dersAssociationcriteria[16]andvascular
dementiabasedonhistoryofvasculardis-
ease, Hachinski score [16], and magnetic
resonance imaging whenever possible).
Deﬁnition of metabolic syndrome
Baselinemetabolicsyndromewasdeﬁned
according to the National Cholesterol Edu-
cation Program Adult Treatment Panel III
(NCEPATPIII)criteria,whichrequiresthe
presence of three or more alterations
among the following cardiometabolic pa-
rameters (being dichotomized as present
or absent): 1) elevated systolic (130
mmHg) or diastolic blood pressure (85
mmHg) or use of antihypertensive medi-
cation, 2) large waist circumference (88
cm in women and 102 cm in men), 3)
high triglycerides (150 mg/dl), 4) low
HDL cholesterol (men 40 and women
50 mg/dl), and 5) elevated fasting gly-
cemia (110 mg/dl) or nonfasting gly-
cemia (200 mg/dl) or antidiabetes
medication (17).
To better understand the speciﬁc role
of diabetes versus impaired fasting glu-
cose, we made further analyses distin-
guishing subjects with diabetes (fasting
glycemia 126 mg/dl or nonfasting gly-
cemia 200 mg/dl or antidiabetes medi-
cation)(1999WorldHealthOrganization
criteria) (18), subjects with impaired fast-
ingglucose(fastingglycemia110mg/dl
without diabetes), and those with normal
fasting glycemia (110 mg/dl) without
diabetes (category of reference, subjects
with no glucose regulation disorder).
Assessment of metabolic syndrome
components
Blood pressure was measured twice in a
sitting position using a digital electronic
tensiometer, and the average was used in
the statistical analyses. Height, weight,
and waist circumference were measured
in lightly dressed subjects. Waist circum-
ference was measured between the lower
rib margin and the iliac crest following a
normal expiration. All pharmacological
treatments taken during the month pre-
ceding the time of the interview were re-
corded. Medical prescriptions and, when
feasible, the medications themselves were
checked by the interviewer.
Blood samples were collected (EDTA
plasma samples stored at 80°C), and
centralized measurements of fasting
blood glucose, HDL cholesterol, and trig-
lycerides were performed. As we had to
include only type 2 diabetic patients by
virtue of the deﬁnition of the metabolic
syndrome component (17), we excluded
patients who were considered to have
type 1 diabetes based on the deﬁnition of
the World Health Organization 1999 cri-
teria(18)andwhoweretreatedbyinsulin
alone (n  26).
Potential confounders and effect
modiﬁers
Sociodemographic information recorded
at baseline during a face-to-face interview
included age, sex, and educational level
(intwoclasses:subjectswhoreceivedpri-
mary or no education versus the others [6
years of schooling or more] and 10 miss-
ing data). Determination of the apoli-
poprotein (apo) E genotype was carried
out at the Lille Genopole, located in Lille,
France (http://www.genopole-lille.fr/
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tial risk factors of dementia (1) and might
be associated with some metabolic syn-
drome components, thus acting as poten-
tial confounders.
Statistical analysis
Baseline characteristics of the subjects
were compared according to the presence
of metabolic syndrome using Student’s t
and Pearson 
2 tests for continuous and
categoricalvariables,respectively.Associ-
ations between metabolic syndrome, or
each of its components, with incident de-
mentia over 4 years were estimated using
separate proportional hazards models
with delayed entry and age as time scale
(9). This model allowed estimation of the
strength of the association between meta-
bolic syndrome and each of its compo-
nents with age at onset of dementia,
taking censoring by death or loss to
follow-upintoaccount,overthe4yearsof
follow-up. All metabolic syndrome com-
ponents were then included in a single
model to evaluate their own independent
effect on the risk of dementia. Models
tested associations with all-cause demen-
tia and its different subtypes (Alzheimer’s
disease/vascular dementia). Models were
adjustedforsociodemographiccharacter-
istics (age [already taken into account by
the model], sex, education level, and
study center). We tested the potential in-
teractions between each component of
the metabolic syndrome and apoE geno-
type(presenceofatleastoneversusnoε 4
allele) on the risk of incident dementia. If
no signiﬁcant interaction was detected,
analysis was further adjusted on the apoE
genotype. We also tested the interaction
between age and waist circumference. All
statistical tests were two sided, and a P
value of 0.05 was considered statisti-
callysigniﬁcant,exceptfortheinteraction
terms, for which a level of signiﬁcance of
0.10 was used in order to better identify
biologically meaningful associations. Sta-
tistical analyses were performed with the
SAS Statistical Package release 9.1 (SAS
Institute, Cary, NC).
RESULTS
General baseline characteristics
The study sample consisted of 4,323
women and 2,764 men who had at least
one reexamination over 4 years and for
whom all metabolic syndrome compo-
nentsweremeasuredatbaseline.The651
subjects with no follow-up did not differ
signiﬁcantly from the 7,087 subjects hav-
ing at least one reexamination in terms of
metabolic syndrome components (P 
0.07 for hypertension, P  0.12 for high
waist circumference, P  0.22 for high
triglycerides,P0.10forelevatedfasting
glycemia;datanotshown),exceptforlow
HDL cholesterol (P  0.001), which was
more frequent in subjects with no fol-
low-up (data not shown).
The baseline characteristics of the
wholecohortaccordingtothepresenceof
metabolicsyndromearereportedinTable
1.Meanagewas73.4(4.9)years.Accord-
ing to the NCEP ATP III criteria, meta-
bolic syndrome was present in 15.8% of
the study participants. Subjects with met-
abolic syndrome were more often men
and slightly older and less educated than
thosewithoutmetabolicsyndrome.There
were no differences in the prevalence of
the apoE ε 4 allele between the two
groups.Highbloodpressurewasthemost
frequent metabolic syndrome compo-
nent, followed by high waist circumfer-
ence, high triglycerides, low HDL
cholesterol, and elevated fasting glyce-
mia. About two-thirds of participants
with hyperglycemia so deﬁned had
diabetes.
Associations between metabolic
syndrome at baseline, its
components, and incident dementia
during follow-up
During 4 years of follow-up, 208 incident
casesofall-causedementiawerevalidated
(i.e., 0.84 incident dementia cases per
100 person-years [95% CI 0.72–0.95]).
This incidence was 1.13 (0.79–1.46) per
100 person-years in subjects with meta-
Table 1—Baseline characteristics according to the presence of metabolic syndrome and associations between the different components of the
metabolic syndrome: the 3C Study, France, 1999–2004
Metabolic
syndrome
No
metabolic
syndrome P
Components of the metabolic syndrome
Total
cohort
High blood
pressure
High waist
circumference
High
triglycerides
Low HDL
cholesterol
High
glycemia
n 7,087 1,121 5,966 6,064 2,049 1,247 741 816
Age (years) 73.4  4.9 73.8  4.8 73.4  4.9 0.05 73.7  4.9 74.0  4.9 73.3  4.9 73.6  4.9 73.2  4.7
Men (%) 39.0 41.6 38.5 0.05 40.8 32.3 45.9 35.4 39.0
Education level (no or
primary) 23.6 29.1 22.6 0.0001 24.4 28.8 25.9 29.9 23.6
ApoE 4* 20.4 21.0 20.3 0.60 20.3 19.6 20.4 23.5 20.4
High blood pressure† 85.6 98.2 83.2 0.0001 NA 91.6 90.0 88.3 95.2
High waist circumference‡ 28.9 78.5 19.6 0.0001 31.0 NA 44.2 50.4 50.2
High triglycerides§ 17.6 66.4 8.4 0.0001 18.5 26.9 NA 50.5 32.0
Low HDL cholesterol 10.5 47.6 3.5 0.0001 10.8 18.3 30.2 NA 22.8
High glycemia¶ 11.5 47.6 4.7 0.0001 12.9 20.0 20.9 25.0 NA
Impaired fasting glucose
without diabetes** 3.9 15.3 1.8 0.0001 4.3 6.9 6.1 7.0 34.2
Diabetes†† 7.6 32.3 2.9 0.0001 8.6 13.1 14.8 18.0 65.8
Data are means  SD or percent. Metabolic syndrome was deﬁned by the NCEP ATP III criteria.*ApoE 4: presence of at least one allele 4 in apoE genotype.
†Systolic blood pressure 130 mmHg or diastolic blood pressure 85 mmHg or medication. ‡Waist circumference 88 cm in women or 102 cm in men.
§Triglycerides 150 mg/dl. HDL cholesterol 50 mg/dl in women or 40 mg/dl in men. ¶Fasting glycemia 110 mg/dl or nonfasting glycemia 200 mg/dl or
antidiabetes medication. **Impaired fasting glucose 110 mg/dl without diabetes. ††Diabetes: fasting glycemia 126 mg/dl or nonfasting glycemia 200 mg/dl
or antidiabetes medication. P value: Student and Pearson 
2 tests used for continuous and categorical variables, respectively, to compare baseline characteristics
between subjects with metabolic syndrome and those without. NA, nonapplicable.
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(0.66–0.90) in the others (164 cases).
TheincidenceofAlzheimer’sdisease(134
cases, 64% of dementia cases) was 0.54
(0.45–0.63) per 100 person-years in the
whole cohort, 0.51 (0.29–0.74) in sub-
jectswithmetabolicsyndrome(20cases),
and 0.55 (0.45–0.65) in the others (114
cases). The incidence of vascular demen-
tia (40 cases, 19.2% of dementia cases)
was 0.16 (0.11–0.21) per 100 person-
years in the whole cohort, 0.33 (0.15–
0.51) in subjects with metabolic
syndrome (13 cases), and 0.13 (0.08–
0.18) in the others (27 cases).
Subjects with metabolic syndrome at
baseline had a nonsigniﬁcant increased
risk of all-cause dementia over 4 years
(Table 2). Table 2 also reports the associ-
ation between each component of meta-
bolic syndrome and the risk of all-cause
dementiaover4yearsoffollow-upinsep-
arate models. High triglyceride level at
baseline was the only component signiﬁ-
cantlyassociatedwithall-causedementia,
the risk being increased by 45%. This as-
sociation remained signiﬁcant and virtu-
ally unchanged after additional
adjustment on apoE genotype (hazard ra-
tio 1.47 [95% CI 1.06–2.03]; P  0.02).
Regardingthelinkbetweenmetabolic
syndrome and the risk of dementia sub-
types, no association was found between
metabolic syndrome at baseline and the
risk of Alzheimer’s disease over 4 years
(Table 2). None of the metabolic syn-
drome components was associated with a
signiﬁcantly increased risk of Alzheimer’s
disease. On the contrary, a high waist cir-
cumference was associated with a de-
creased risk of Alzheimer’s disease (Table
2). This association remained unchanged
after additional adjustment of apoE geno-
type (hazard ratio 0.62 [95% CI 0.41–
0.92]; P  0.02).
Subjects with metabolic syndrome at
baseline had a signiﬁcantly increased risk
of vascular dementia over 4 years (Table
2), even after additional adjustment on
apoE4 genotype (hazard ratio 2.44 [95%
CI 1.25–4.77]; P  0.01). High triglycer-
ide level was the only component signiﬁ-
cantly associated with vascular dementia.
This signiﬁcant association persisted after
additional adjustment of the apoE geno-
type (2.36 [1.21–4.61]; P  0.02). Ele-
vated fasting glycemia at baseline
according to the NCEP ATP III criteria
was not signiﬁcantly associated with in-
creased risk of incident dementia. How-
ever,whenthisvariablewassplitintotwo
dummy variables, the presence of diabe-
tes was signiﬁcantly associated with in-
creased risk of all-cause and vascular
dementia, not Alzheimer’s disease, while
impaired fasting glucose was not associ-
ated with any type of dementia (Table 2).
Therewasnointeractionbetweenageand
waist circumference. (P  0.44 in the
model with all-cause dementia, P  0.76
in the model with Alzheimer’s disease,
and P  0.45 in the model with vascular
dementia). We also found no interaction
betweenageandelevatedfastingglycemia
for the risk of all-cause dementia (P 
0.78), Alzheimer’s disease (P  0.24), or
vascular dementia (P  0.23) (data not
shown).
The results remained unchanged
whenallﬁvemetabolicsyndromecompo-
nents were entered simultaneously as ex-
planatory variables in a single model
(Table 2, bottom, single model). In this
analysis, the results for each metabolic
syndrome component were similar to
those obtained with separate regressions
with each component. Hazard ratios and
signiﬁcance levels were only slightly at-
tenuated because of some collinearity
among metabolic syndrome components.
Similarly, diabetes but not impaired fast-
ing glucose remained associated with risk
of all-cause and vascular dementia when
adjusting for the other metabolic syn-
drome components.
CONCLUSIONS — In this prospec-
tive study of French noninstitutionalized
elderlysubjectsaged65years,thepres-
ence of metabolic syndrome (NCEP ATP
IIIcriteria)atbaselinewasassociatedwith
an increased risk of incident vascular de-
Table 2—Association between the metabolic syndrome at baseline or each of its components (in separate models and then in a single model)
and risk for incident dementia over 4 years: the 3C Study, France, 1999–2004
All-cause dementia P Alzheimer’s disease P Vascular dementia P
n 7,077 7,077 7,077
Separate models
Metabolic syndrome 1.28 (0.92–1.80) 0.15 0.81 (0.50–1.31) 0.39 2.42 (1.24–4.73) 0.01
High blood pressure* 1.07 (0.66–1.72) 0.79 1.06 (0.58–1.92) 0.86 3.82 (0.52–27.91) 0.19
High waist circumference† 0.86 (0.64–1.17) 0.34 0.63 (0.43–0.94) 0.02 0.82 (0.41–1.66) 0.58
High triglycerides‡ 1.45 (1.05–2.00) 0.02 0.90 (0.57–1.43) 0.67 2.27 (1.16–4.42) 0.02
Low HDL cholesterol§ 1.22 (0.82–1.81) 0.33 0.76 (0.42–1.35) 0.34 2.06 (0.94–4.53) 0.07
High glycemia 1.28 (0.88–1.88) 0.20 1.04 (0.62–1.74) 0.89 1.89 (0.89–4.02) 0.10
Variable high glycemia (split into two variables)
Impaired fasting glucose¶ 0.63 (0.26–1.53) 0.30 0.79 (0.29–2.16) 0.65 0.63 (0.09–4.60) 0.64
Diabetes** 1.58 (1.05–2.38) 0.03 1.15 (0.64–2.05) 0.64 2.53 (1.15–5.66) 0.02
Single model
High blood pressure* 1.06 (0.65–1.70) 0.83 1.10 (0.60–2.01) 0.75 3.73 (0.51–27.4) 0.20
High waist circumference† 0.83 (0.61–1.12) 0.22 0.64 (0.43–0.95) 0.03 0.65 (0.31–1.33) 0.24
High triglycerides‡ 1.42 (1.00–2.01) 0.05 1.00 (0.61–1.64) 0.998 1.98 (0.95–4.13) 0.07
Low HDL cholesterol§ 1.05 (0.68–1.62) 0.81 0.80 (0.43–1.48) 0.47 1.52 (0.64–3.62) 0.34
High glycemia 1.21 (0.82–1.80) 0.34 1.13 (0.67–1.92) 0.65 1.61 (0.74–3.50) 0.23
Data are hazard ratio (95% CI). Models are adjusted by age, sex, educational level, and city center: n  7077, without missing data. Regressions analyzed by
proportionalhazardsmodelswithdelayedentryandageastimescale.*Systolicbloodpressure130mmHgordiastolicbloodpressure85mmHgormedication.
†Waist circumference 88 cm in women or 102 cm in men. ‡Triglycerides  150 mg/dl. §HDL cholesterol 50 mg/dl in women or 40 mg/dl in men. Fasting
glycemia 110 mg/dl or nonfasting glycemia 200 mg/dl or antidiabetes medication. ¶Impaired fasting glucose: fasting glycemia 110 mg/dl without diabetes.
**Diabetes: fasting glycemia 126 mg/dl or nonfasting glycemia 200 mg/dl or antidiabetes medication.
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Alzheimer’s disease over 4 years, inde-
pendently of sociodemographic charac-
teristics and the apoE ε 4 allele. High
triglyceride level at baseline was the only
metabolic syndrome component that was
signiﬁcantly associated with all-cause de-
mentia and vascular dementia, even after
adjustment of the apoE genotype. On the
other hand, a high waist circumference
was associated with a decreased risk of
Alzheimer’sdisease.Diabetes,butnotim-
paired fasting glucose, was signiﬁcantly
associated with all-cause dementia and
vascular dementia.
Our ﬁndings suggest that the concept
of metabolic syndrome may not give any
additive value in predicting the develop-
mentofdementiacomparedwithitscom-
ponents considered separately. Indeed,
when we tested the contribution of each
metabolic syndrome component by put-
ting them together into a single model,
the results were similar to those obtained
with one regression for each component,
suggesting that the association of each
component with dementia risk was inde-
pendent. Moreover, we found no statisti-
cally signiﬁcant association between the
number of metabolic syndrome compo-
nents and the risk of incident dementia
(data not shown). This result is in agree-
ment with the study of Yaffe et al. (10), in
whichthenumberofmetabolicsyndrome
components did not affect the risk of cog-
nitive decline. Accordingly, the concept
of metabolic syndrome is controversial
and the metabolic syndrome would be “a
set of statistical associations believed to
carry an excess of cardiovascular risk”
(20) and then of vascular dementia.
The association between high triglyc-
eride level at baseline and risk of incident
dementiaisanoriginalﬁnding.Fewstud-
ies have focused on hypertriglyceridemia
and its relation to dementia. A transversal
study (21) made known the potential re-
lationship between elevated triglyceride
levels and poorer cognitive function in
patients with diabetes. A similar associa-
tion was found in a longitudinal study
with a long-term follow-up (in the Hono-
lulu-Asia Aging Study, a 1 SD increase in
triglyceride levels during mid-life in-
creasedtheriskofdementia25yearslater
[9]). In our study, high triglyceride level
was only associated with incident vascu-
lar dementia (even if there were only 40
cases) but not with Alzheimer’s disease.
Whether moderate hypertriglyceridemia
is an independent risk factor for cardio-
vascular disease remains a debate, but a
meta-analysisofthousandsofpatientsfol-
lowed-up for 10 years showed that a
triglyceride elevation of 1 mmol/l in-
creased the risk of cardiovascular disease,
independently of HDL cholesterol (22).
However, the precise mechanisms, espe-
cially in the brain, by which hypertriglyc-
eridemia might increase dementia risk
still have to be elucidated. Few studies
have examined the relationship between
HDLcholesterolandincidenceofdemen-
tia, most focusing on total or LDL choles-
terol with conﬂicting results (23).
The fact that diabetes itself (and not
impaired fasting glucose) was associated
with all-cause and vascular dementia but
not Alzheimer’s disease reinforces the hy-
pothesis that vascular risk factors are in-
volved. Vascular pathophysiological
mechanisms are more involved in diabe-
tes than in impaired fasting glucose. In-
deed, “diabetes” is deﬁned by risk of
microvascular complications (18) (as oc-
currence of microanevrysms).
In opposition with our results, higher
waist circumference was found to be as-
sociated with higher risk of Alzheimer’s
disease but only in individuals aged 76
years (24). Conversely, some studies
found that patients might lose weight be-
fore Alzheimer’s disease diagnosis, and
this has been interpreted as a conse-
quence of the disease rather than a risk
factor.So,theinverseassociationbetween
adiposity, measured by waist circumfer-
ence, and Alzheimer’s disease could be
explained by weight loss due to preclini-
cal disease in our participants.
In contrast to other studies (3), we
found no association between hyperten-
sion and risk of developing dementia.
Thiscouldbeduetothehighfrequencyof
hypertension in the whole 3C Study co-
hort. Therefore, the relationship between
hypertension at middle age and risk of
dementia (25) may no longer hold at
older ages. Moreover, in our study, the
duration of the presence of the various
components of metabolic syndrome was
not known and may have inﬂuenced the
risk of dementia. Indeed, risk factors that
are already present at mid-life might have
a stronger impact on dementia risk (e.g.,
hypertension) (25). Results from several
studies indicate that the relation between
these factors and disease become increas-
ingly complex with advancing age (24).
Findings may therefore be different when
the risk factors are measured at mid-life,
in particular for hypertension and low
HDL cholesterol but also for BMI (25).
Another explanation for the lack of asso-
ciationinourstudymaylieinthefactthat
the thresholds currently used for deﬁning
metabolic syndrome might not be suit-
able for an older population, as suggested
by the very high prevalence of hyperten-
sionfoundinoursampleofratherhealthy
participants.
Nevertheless, several limitations may
affect the interpretation of our results. Se-
lective survival might explain some para-
doxical results in the oldest elderly
subjects, in whom metabolic syndrome
was found to be associated with slower
cognitive decline. The association be-
tween metabolic syndrome and dementia
might indeed be underestimated as a re-
sult of censoring for death since subjects
with metabolic syndrome are more likely
to die from cardiovascular disease before
developing dementia. It would be inter-
esting, in a future study, to explore the
causes of death in patients with metabolic
syndrome. Similarly, 651 subjects with
no follow-up did not differ signiﬁcantly
from 7,087 subjects having at least one
reexamination in terms of metabolic syn-
drome components, except for HDL cho-
lesterol, which could be explained by a
worse nutritional status linked to higher
cumulative mortality rates (data not
shown).
Our results emphasize the need for
early detection and treatment of hypertri-
glyceridemia and diabetes in older indi-
viduals in order to delay the onset of
clinical dementia. However, the concept
of metabolic syndrome as a whole does
not seem to have any added value regard-
ing dementia risk in this population. The
putative interactions between single met-
abolic risk factors (high triglyceride level
and diabetes) and dementia need to be
further studied.
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